Genmab — August 2020
-
BNT311, the anti-PD-L1/anti-4-1BB bispecific antibody that combine constitutive TPI blockade and conditional costimulatory activity, a mechanism of action which led to enhanced proliferation of antigen-specific activated T cells in the presence of PD-L1 positive cells in preclinical studies. Based on the preclinical data we have generated, we believe this molecule could represent a powerful new checkpoint immune modulator with seropositive potential across a range of solid tumors.
-
Ikke på hjemmesiden?
-
Ikke i den vigtigste finanskalender: https://www.proinvestor.com/chathistory/-120/finanskalender
-
Den er tjekket op mod 3-4 andre kilder hver gang.
-
Helt præcist: https://ir.genmab.com/financial-calendar#content
-
I mediernes og bankernes kalendere har der stået kl. 17 i årevis. Vi er vant til at det kommer lidt senere.
-
Reviderer op - nice!
-
Var lidt urolig omkring usddkk, men de fastholder
-
Fastholder spænd på omkostninger
-
...det er så også nyt...
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind